Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 485.89 USD -2.92% Market Closed
Market Cap: 124.9B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+29%
Revenue
Forecast
+19%
Operating Income
Forecast
+26%
Net Income
Forecast
+24%

Wall Street
Price Targets

VRTX Price Targets Summary
Vertex Pharmaceuticals Inc

Wall Street analysts forecast VRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRTX is 512.28 USD with a low forecast of 333.3 USD and a high forecast of 645.75 USD.

VRTX Lowest Forecast
Wall Street Target
333.3 USD
31% Downside
VRTX Average Forecast
Wall Street Target
512.28 USD
5% Upside
VRTX Highest Forecast
Wall Street Target
645.75 USD
33% Upside
Lowest
Price Target
333.3 USD
31% Downside
Average
Price Target
512.28 USD
5% Upside
Highest
Price Target
645.75 USD
33% Upside
Vertex Pharmaceuticals Inc Competitors:
Price Targets
ARTV
Artiva Biotherapeutics Inc
831% Upside
ADAG
Adagene Inc
552% Upside
300896
Imeik Technology Development Co Ltd
33% Upside
L
LYTIX
Lytix Biopharma AS
186% Upside
ARTV
Artiva Biotherapeutics Inc
831% Upside
ADAG
Adagene Inc
552% Upside
300896
Imeik Technology Development Co Ltd
33% Upside
L
LYTIX
Lytix Biopharma AS
186% Upside
ORKA
Oruka Therapeutics Inc
372% Upside
NBIX
Neurocrine Biosciences Inc
66% Upside
TWST
Twist Bioscience Corp
52% Upside
SYRE
Spyre Therapeutics Inc
353% Upside

Revenue
Forecast

Revenue Estimate
Vertex Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 26%. The projected CAGR for the next 3 years is 10%.

26%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Vertex Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's operating income is 111%. The projected CAGR for the next 3 years is 15%.

111%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-23%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Vertex Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
VRTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRTX stock valuation using valuation multiples.
Wall Street Estimates
VRTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRTX's stock price target?
Price Target
512.28 USD

According to Wall Street analysts, the average 1-year price target for VRTX is 512.28 USD with a low forecast of 333.3 USD and a high forecast of 645.75 USD.

What is Vertex Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 26%. The projected CAGR for the next 3 years is 10%.

What is Vertex Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's operating income is 111%. The projected CAGR for the next 3 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.